Login to Your Account



$35M in hand, Delinia 'T's up targeted approach to autoimmune disease

By Marie Powers
News Editor

Friday, September 16, 2016

Delinia Inc.'s $35 million series A sets up the startup to drive straight down the fairway in targeting regulatory T cells (Tregs) to treat autoimmune diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription